Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)

Summary

Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults.

As usual NHS ChoicesBehind the Headlines offers due perspective, without over-dampening readers’ enthusiasm.

Full Text Link

Reference

Promising Alzheimer’s drug ‘clears early hurdle’. London: NHS Choices; Behind the Headlines, November 3rd 2016.

This relates to:

Full Text Link

Reference

Kennedy, ME. Stamford, AW. [and] Chen, X. [et al] (2016). The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients. Science Translational Medicine. November 2nd 2016. [Epub ahead of print].

Possibly of interest:

Full Text Link

Reference

Yan, R. (2016). Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs. Translational Neurodegeneration. July 2016. 14(5): 13.

Trials Halted in 2018

Hopes dashed: further development of the drug has since stopped.

“An external Data Monitoring Committee (eDMC) had recommended halting the trial after an interim safety analysis found the likelihood of benefits didn’t outweigh the risks”.

Full Text Link

Reference

Terry, M. (2018). Phase III APECS study investigating verubecestat for Alzheimer’s Disease fails to meet primary endpoint. [Online, USA]: Biospace Inc., February 19th 2018.

Advertisements

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in Animal Studies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Choices, Pharmacological Treatments, Quick Insights, Universal Interest and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.